Encapsulation and release of the hypnotic agent zolpidem from biodegradable polymer microparticles containing hydroxypropyl-beta-cyclodextrin.
The goal of this study was to design a prolonged release system of the hypnotic agent zolpidem (ZP) useful for the treatment of insomnia. In this work, ZP alone or in the presence of HP-beta-CD was encapsulated in microparticles constituted by poly(DL-lactide) (PDLLA) and poly(DL-lactide-co-glycolide) (PLGA) and the drug release from these systems was evaluated. ZP alone-loaded microparticles were prepared by the classical O/W emulsion-solvent evaporation method. Conversely, ZP/HP-beta-CD containing microparticles were prepared by the W/O/W emulsion-solvent evaporation method following two different procedures (i.e. A and B). Following procedure A, the previously produced ZP/HP-beta-CD solid complex was added to the water phase of primary emulsion. In the procedure B, HP-beta-CD was added to the aqueous phase and ZP to the organic phase. The resulting microparticles were characterized about morphology, size, encapsulation efficiency and release rates. FT-IR, X-ray, and DSC results suggest the drug is in an essentially amorphous state within the microparticles. The release profiles of ZP from microparticles were in general biphasic, being characterized by an initial burst effect and a subsequent slow ZP release. It resulted that co-encapsulating ZP with or without HP-beta-CD in PDLLA and PLGA the drug release from the corresponding microparticles was protracted. Moreover, in a preliminary pharmacological screening, the ataxic activity in rats was investigated and it was found that intragastric administration of the ZP/HP-beta-CD/PLGA microparticles prepared according to procedure B produced the same ataxic induction time as the one induced by the currently used formulation Stilnox. Interestingly moreover, there was a longer ataxic lasting and a lower intensity of ataxia produced by the ZP/HP-beta-CD/PLGA-B-formulation already after 60 min following the administration. However, a need for further pharmacokinetic and pharmacodynamic studies resulted to fully evaluate the utility of this last formulation for the sustained delivery of ZP.
Trapani
Giuseppe
G
Dipartimento Farmaco-Chimico, Facoltà di Farmacia, Università degli Studi di Bari, Via Orabona 4, 70125 Bari, Italy. trapani@farmchim.uniba.it
Lopedota
Angela
A
Boghetich
Giancarlo
G
Latrofa
Andrea
A
Franco
Massimo
M
Sanna
Enrico
E
Liso
Gaetano
G
D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000818:Animals; D001259:Ataxia / Q000139:chemically induced; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D003505:Cyclodextrins; D005079:Excipients; D006993:Hypnotics and Sedatives / Q000008:administration & dosage* / Q000633:toxicity; D008297:Male; D010316:Particle Size; D011725:Pyridines / Q000008:administration & dosage* / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077334:Zolpidem; D047392:beta-Cyclodextrins
D003505:Cyclodextrins; D005079:Excipients; D006993:Hypnotics and Sedatives; D011725:Pyridines; D047392:beta-Cyclodextrins; D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000077334:Zolpidem